A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-dose, Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 in Patients With Achalasia
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs IW 1701 (Primary)
- Indications Achalasia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ironwood Pharmaceuticals
- 02 Nov 2017 According to an Ironwoord Pharmaceuticals media release, due to slower than expected enrollment data from this study are now expected in 2018.
- 01 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Jul 2018.
- 01 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2018.